Georgios Tsakonas

849 total citations
48 papers, 577 citations indexed

About

Georgios Tsakonas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Georgios Tsakonas has authored 48 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Georgios Tsakonas's work include Lung Cancer Treatments and Mutations (27 papers), Lung Cancer Research Studies (22 papers) and Brain Metastases and Treatment (11 papers). Georgios Tsakonas is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Lung Cancer Research Studies (22 papers) and Brain Metastases and Treatment (11 papers). Georgios Tsakonas collaborates with scholars based in Sweden, Greece and Norway. Georgios Tsakonas's co-authors include Simon Ekman, Luigi De Petris, Konstantinos Rounis, Signe Friesland, Rolf Lewensohn, Odd Terje Brustugun, Signe Risum, Tine Schytte, Bjørn Henning Grønberg and Øystein Fløtten and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Molecular Sciences.

In The Last Decade

Georgios Tsakonas

45 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Georgios Tsakonas Sweden 14 344 295 145 85 68 48 577
Hongwei Li China 13 244 0.7× 223 0.8× 136 0.9× 41 0.5× 62 0.9× 47 535
Anna Mucha-Małecka Poland 12 169 0.5× 119 0.4× 145 1.0× 61 0.7× 91 1.3× 46 462
Lydia Dreosti South Africa 10 300 0.9× 179 0.6× 157 1.1× 27 0.3× 75 1.1× 20 472
Mustafa Dikilitaş Türkiye 12 327 1.0× 210 0.7× 107 0.7× 34 0.4× 55 0.8× 39 600
Alessandro Iaculli Italy 10 252 0.7× 76 0.3× 133 0.9× 90 1.1× 93 1.4× 17 517
Vittorio Ferrari Italy 14 225 0.7× 180 0.6× 99 0.7× 30 0.4× 60 0.9× 56 480
Erdem Çubukçu Türkiye 12 253 0.7× 75 0.3× 106 0.7× 59 0.7× 103 1.5× 51 481
Nathan D. Seligson United States 13 213 0.6× 165 0.6× 192 1.3× 27 0.3× 108 1.6× 38 532
Nikolaos Syrigos Greece 12 279 0.8× 190 0.6× 187 1.3× 29 0.3× 91 1.3× 61 599
Jing Cheng China 13 118 0.3× 121 0.4× 134 0.9× 42 0.5× 115 1.7× 39 402

Countries citing papers authored by Georgios Tsakonas

Since Specialization
Citations

This map shows the geographic impact of Georgios Tsakonas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georgios Tsakonas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georgios Tsakonas more than expected).

Fields of papers citing papers by Georgios Tsakonas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georgios Tsakonas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georgios Tsakonas. The network helps show where Georgios Tsakonas may publish in the future.

Co-authorship network of co-authors of Georgios Tsakonas

This figure shows the co-authorship network connecting the top 25 collaborators of Georgios Tsakonas. A scholar is included among the top collaborators of Georgios Tsakonas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georgios Tsakonas. Georgios Tsakonas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grønberg, Bjørn Henning, Øystein Fløtten, Maria Moksnes Bjaanæs, et al.. (2025). High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. Journal of Thoracic Oncology. 20(8). 1108–1119. 1 indexed citations
2.
Tsakonas, Georgios, Per Hydbring, Kenbugul Jatta, et al.. (2024). Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study. Translational Lung Cancer Research. 13(11). 2918–2933. 1 indexed citations
3.
4.
Tsakonas, Georgios, et al.. (2023). Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis. International Journal of Cancer. 153(9). 1556–1567. 8 indexed citations
5.
6.
7.
Alexeyenko, Andrey, Odd Terje Brustugun, Radosveta Gencheva, et al.. (2022). Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients. Translational Lung Cancer Research. 11(10). 2064–2078. 4 indexed citations
8.
Rounis, Konstantinos, et al.. (2021). Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Cancer. 145. 245–254. 63 indexed citations
9.
Grønberg, Bjørn Henning, Øystein Fløtten, Odd Terje Brustugun, et al.. (2021). High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet Oncology. 22(3). 321–331. 76 indexed citations
10.
Rounis, Konstantinos, Dimitrios Makrakis, Nikolaos Galanakis, et al.. (2021). 1299P Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Annals of Oncology. 32. S1006–S1006.
11.
Tsakonas, Georgios, Johan Botling, Patrick Micke, et al.. (2019). c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. Lung Cancer. 133. 69–74. 24 indexed citations
12.
Grozman, Vitali, et al.. (2018). Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer. 120. 75–81. 13 indexed citations
13.
Tsakonas, Georgios & Simon Ekman. (2018). Oncogene-addicted non-small cell lung cancer and immunotherapy. Journal of Thoracic Disease. 10(S13). S1547–S1555. 26 indexed citations
14.
Tsakonas, Georgios, Luigi De Petris, & Simon Ekman. (2017). Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies. Cancer Treatment Reviews. 54. 122–131. 43 indexed citations
15.
Skalkidou, Alkistis, Georgios Tsakonas, Lena Brandt, et al.. (2013). Cancer incidence and mortality patterns in women with anorexia nervosa. International Journal of Cancer. 134(7). 1751–1757. 23 indexed citations
16.
Kosmas, Christos, George Vorgias, Georgios Tsakonas, et al.. (2011). Paclitaxel–ifosfamide–carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours. British Journal of Cancer. 105(7). 897–902. 2 indexed citations
17.
Pipilis, Athanasios, George Lazaros, Georgios Tsakonas, & Christodoulos Stefanadis. (2010). Triple antithrombotic therapy with aspirin, a thienopyridine derivative plus oral anticoagulation in patients with atrial fibrillation undergoing coronary stenting.. PubMed. 51(4). 330–7. 5 indexed citations
18.
Tsakonas, Georgios & Christos Kosmas. (2008). Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.. PubMed. 12(3). 319–27. 5 indexed citations
19.
Kosmas, Christos, N. Tsavaris, N. Mylonakis, et al.. (2007). Docetaxel-Ifosfamide Combination in Patients with Advanced Breast Cancer Failing Prior Anthracycline- Based Regimens: Results of a Phase I-II Study. Journal of Chemotherapy. 19(3). 322–331. 3 indexed citations
20.
Karabelis, A., Christos Kosmas, N. Mylonakis, et al.. (2006). Paclitaxel (P), pegylated liposomal doxorubicin (PLD) and trastuzumab as 1st-line chemotherapy (chemo) in HER2/neu-positive (+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 24(18_suppl). 10663–10663. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hongwei Li Breakdown of academic impact, for papers by Anna Mucha-Małecka Breakdown of academic impact, for papers by Lydia Dreosti Breakdown of academic impact, for papers by Mustafa Dikilitaş Breakdown of academic impact, for papers by Alessandro Iaculli Breakdown of academic impact, for papers by Vittorio Ferrari Breakdown of academic impact, for papers by Erdem Çubukçu Breakdown of academic impact, for papers by Nathan D. Seligson Breakdown of academic impact, for papers by Nikolaos Syrigos Breakdown of academic impact, for papers by Jing Cheng
Rankless by CCL
2026